Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tommaso Porcelli

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Endocrine|February 4, 2021
Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institutionTommaso Porcelli, Cristina Luongo, Francesca Sessa, et al.
Endocrinology|March 10, 2025
Type 2 Deiodinase Promotes Fatty Adipogenesis in Muscle Fibroadipogenic Progenitors From Adult Male MiceCristina Luongo, Daniela Di Girolamo, Raffaele Ambrosio, et al.
European Thyroid Journal|January 22, 2025
Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?Tommaso Porcelli, Cristina Luongo, Anna Cerbone, et al.
Endocrine-Related Cancer|January 24, 2023
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitorsTommaso Porcelli, Raffaele Ambrosio, Maria Angela De Stefano, et al.
International Journal of Molecular Sciences|June 13, 2025
Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate Syndrome-Linked p63 Mutations Disrupt Keratinocyte Proliferation and Survival Through Oxidative Stress and Impaired Slc7a11 ExpressionDaniela Di Girolamo, Sara Palumbo, Dario Antonini, et al.
The Journal of Clinical Investigation|March 5, 2026
Type 2 deiodinase-dependent surge in thyroid hormone controls muscle stem cell quiescence and self-renewalMaria Angela De Stefano, Raffaele Ambrosio, Cristina Luongo, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient PatientsMaria Grazia Castagna, Monica Dentice, Silvia Cantara, et al.
JCO Precision Oncology|August 3, 2023
D898_E901 <i>RET</i> Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent MechanismsTommaso Porcelli, Marialuisa Moccia, Maria Angela De Stefano, et al.
Frontiers in Nutrition|July 5, 2022
Adherence to the Mediterranean Diet as a Modifiable Risk Factor for Thyroid Nodular Disease and Thyroid Cancer: Results From a Pilot StudyLuigi Barrea, Giovanna Muscogiuri, Giulia de Alteriis, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case ReportCristina Luongo, Tommaso Porcelli, Francesca Sessa, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Endocrine|February 4, 2021
Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institutionTommaso Porcelli, Cristina Luongo, Francesca Sessa, et al.
Endocrinology|March 10, 2025
Type 2 Deiodinase Promotes Fatty Adipogenesis in Muscle Fibroadipogenic Progenitors From Adult Male MiceCristina Luongo, Daniela Di Girolamo, Raffaele Ambrosio, et al.
European Thyroid Journal|January 22, 2025
Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?Tommaso Porcelli, Cristina Luongo, Anna Cerbone, et al.
Endocrine-Related Cancer|January 24, 2023
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitorsTommaso Porcelli, Raffaele Ambrosio, Maria Angela De Stefano, et al.
International Journal of Molecular Sciences|June 13, 2025
Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate Syndrome-Linked p63 Mutations Disrupt Keratinocyte Proliferation and Survival Through Oxidative Stress and Impaired Slc7a11 ExpressionDaniela Di Girolamo, Sara Palumbo, Dario Antonini, et al.
The Journal of Clinical Investigation|March 5, 2026
Type 2 deiodinase-dependent surge in thyroid hormone controls muscle stem cell quiescence and self-renewalMaria Angela De Stefano, Raffaele Ambrosio, Cristina Luongo, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient PatientsMaria Grazia Castagna, Monica Dentice, Silvia Cantara, et al.
JCO Precision Oncology|August 3, 2023
D898_E901 <i>RET</i> Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent MechanismsTommaso Porcelli, Marialuisa Moccia, Maria Angela De Stefano, et al.
Frontiers in Nutrition|July 5, 2022
Adherence to the Mediterranean Diet as a Modifiable Risk Factor for Thyroid Nodular Disease and Thyroid Cancer: Results From a Pilot StudyLuigi Barrea, Giovanna Muscogiuri, Giulia de Alteriis, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case ReportCristina Luongo, Tommaso Porcelli, Francesca Sessa, et al.
Pageof 4